Vauleon E - Search Results

1

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D. Quillien V, et al. Among authors: vauleon e. Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191. Cancer Biomark. 2017. PMID: 28800313 Free article.

2

The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.

Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, Delattre JY, Thillet J, Sanson M. Vauleon E, et al. Cancer Genet Cytogenet. 2007 Jan 1;172(1):33-7. doi: 10.1016/j.cancergencyto.2006.07.013. Cancer Genet Cytogenet. 2007. PMID: 17175377

3

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.

Avril T, Saikali S, Vauleon E, Jary A, Hamlat A, De Tayrac M, Mosser J, Quillien V. Avril T, et al. Among authors: vauleon e. J Neuroimmunol. 2010 Aug 25;225(1-2):22-33. doi: 10.1016/j.jneuroim.2010.04.003. Epub 2010 May 20. J Neuroimmunol. 2010. PMID: 20493562 Free article.

4

Overview of cellular immunotherapy for patients with glioblastoma.

Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Vauleon E, et al. Clin Dev Immunol. 2010;2010:689171. doi: 10.1155/2010/689171. Epub 2010 Oct 4. Clin Dev Immunol. 2010. PMID: 20953324 Free PMC article. Review.

5

DNA methylation in glioblastoma: impact on gene expression and clinical outcome.

Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L, Menei P, Quillien V, Mosser J. Etcheverry A, et al. Among authors: vauleon e. BMC Genomics. 2010 Dec 14;11:701. doi: 10.1186/1471-2164-11-701. BMC Genomics. 2010. PMID: 21156036 Free PMC article.

6

[MGMT analysis in gliomas].

Quillien V, Vauléon E, Saikali S, Lesimple T, Hamlat A, Etcheverry A, Mosser J. Quillien V, et al. Among authors: vauleon e. Bull Cancer. 2011 Mar;98(3):291-303. doi: 10.1684/bdc.2011.1332. Bull Cancer. 2011. PMID: 21459716 Free article. Review. French.

7

Mechanisms of immunomodulation in human glioblastoma.

Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V. Avril T, et al. Among authors: vauleon e. Immunotherapy. 2011 Apr;3(4 Suppl):42-4. doi: 10.2217/imt.11.39. Immunotherapy. 2011. PMID: 21524170 Review.

8

Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.

Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V. Avril T, et al. Among authors: vauleon e. Brain Pathol. 2012 Mar;22(2):159-74. doi: 10.1111/j.1750-3639.2011.00515.x. Epub 2011 Sep 16. Brain Pathol. 2012. PMID: 21790828 Free PMC article.

9

[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].

Vauleon E, Mesbah H, Gedouin D, Lecouillard I, Louvel G, Hamlat A, Riffaud L, Carsin B, Quillien V, Audrain O, Lesimple T. Vauleon E, et al. Bull Cancer. 2012 Feb 1;99(2):121-6. doi: 10.1684/bdc.2011.1528. Bull Cancer. 2012. PMID: 22257744 Free article. French.

10

Immune genes are associated with human glioblastoma pathology and patient survival.

Vauléon E, Tony A, Hamlat A, Etcheverry A, Chiforeanu DC, Menei P, Mosser J, Quillien V, Aubry M. Vauléon E, et al. BMC Med Genomics. 2012 Sep 14;5:41. doi: 10.1186/1755-8794-5-41. BMC Med Genomics. 2012. PMID: 22980038 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page